Distinct Different Contributions of the Alternative and Classical Complement Activation Pathway for the Innate Host Response during Sepsis

Katja Dahlke(Jena University Hospital), Niels C. Riedemann(Inflarx (Germany))

The Journal of Immunology

January 25, 2011

10.4049/jimmunol.1002741

Cited by 37

Related Papers

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

|The Lancet Rheumatology|2020|199

Regulatory role of C5a in LPS‐induced IL‐6 production by neutrophils during sepsis

|The FASEB Journal|2003|180

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

|The Lancet Respiratory Medicine|2022|143

Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)

|Critical Care Explorations|2021|36